Doyle Ramona 4

4 · RECURSION PHARMACEUTICALS, INC. · Filed Feb 8, 2022

Form 4

Period: 2022-02-04

Chief Medical Officer

Transactions

Award
Class A Common Stock
2022-02-04+38,499→ 95,834 total
Award
Class A Common Stock
2022-02-04+2,392→ 98,226 total
Tax Payment
Class A Common Stock
2022-02-04$11.40/sh−981$11,183→ 97,245 total
Award
Stock Option (Right to Buy)
2022-02-04+76,998→ 76,998 total
Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (76,998 underlying)
Award
Stock Option (Right to Buy)
2022-02-04+4,784→ 4,784 total
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (4,784 underlying)

Holdings

Stock Option (Right to Buy)
Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (694,053 underlying)
694,053

Footnotes (4)

[F1]This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter.
[F2]This RSU vested immediately upon the grant date.
[F3]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
[F4]Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

Documents

1 file